supplementhackr
Osteo Bi-Flex

Osteo Bi-Flex Triple Strength + Turmeric

Serving
2 Tablet(s)
Per container
40
Form
tablet
UPC
030768679309
DSLD
307940
Formula hash
88103a32af8f
Brand context
Osteo Bi-Flex
Catalog
94
products
With avoid flag
16
products
FDA recalls
0
history
CAERS
81
reports
Avoid-flaggedObjective label signals
Flagged excipients
3
1 avoid · 2 caution
FDA recalls
0
no recall history
CAERS reports
19
FDA consumer events
Certifications
0
none recorded
1 avoid-level excipient · Every flag below links to the authority's published citation.
NIH LiverTox
1 ingredient with hepatotoxicity classification
Worst severity: Category C
About LiverTox →
  • TurmericCategory C

    LiverTox Category C. 2020-2024 rise in acute liver injury cases linked specifically to high-dose concentrated turmeric/curcumin extracts with enhanced-bioavailability formulations (piperine, phospholipid complex). Not associated with culinary use.

    LiverTox →

Supplement Facts

5 active ingredients
IngredientAmount% DV
Calories
otherUNII · 1
5 Calorie(s)—
Total Carbohydrates
CarbohydrateotherUNII · 0
1 Gram(s)1%
Glucosamine Hydrochloride
herbUNII · 750W5330FY
1500 mg—
Total Carbohydrates
CarbohydrateotherUNII · 0
100 mg—
Turmeric root powder
TurmericherbUNII · 856YO1Z64F
LiverTox C
450 mg—
Flagged excipients

3 flagged · authority citations

  • ● AVOIDTitanium Dioxide
    color

    Banned in EU food products effective 2022-08 (Commission Regulation (EU) 2022/63) following EFSA Panel opinion that a safe daily intake could not be established due to genotoxicity concerns. Still GRAS in the US under 21 CFR 73.575 but EU position is stricter.

    eur-lex.europa.eu →efsa.europa.eu →ecfr.gov →
  • ◐ CAUTIONFD&C Yellow #5 Lake
    color

    EU requires warning label 'may have an adverse effect on activity and attention in children' per Commission Regulation 1333/2008 Annex III (following Southampton study 2007). FDA requires specific label declaration (21 CFR 74.705).

    eur-lex.europa.eu →ecfr.gov →
  • ◐ CAUTIONFD&C Yellow #6 Lake
    color

    EU requires 'attention in children' warning per Reg 1333/2008 Annex III (Southampton study 2007). Banned in Norway + Finland; allowed in US under 21 CFR 74.706 with declaration.

    eur-lex.europa.eu →
FDA CAERS · adverse event context
19
consumer-submitted adverse event reports filed with the FDA CFSAN Adverse Event Reporting System mentioning this product or its brand.

CAERS reports are unverified consumer submissions — not adjudicated causality. Large well-known brands accumulate proportionally more reports simply due to broader use. About CAERS →

Other ingredients

Cellulose · Crospovidone · Hydroxypropyl Methylcellulose · Stearic Acid · Cellulose · Silica · Magnesium Stearate